Expert Interview
Discussing Bristol Myer's Phase 3 SUCCESSOR-2 study Results Evaluating oral mezigdomide in patients with Relapsed or Refractory Multiple Myeloma.
Ticker(s): BMYInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
What are your overall impressions of the Phase 3 SUCCESSOR-2 results evaluating oral mezigdomide in relapsed or refractory multiple myeloma?
Added By: sara_adminBased on the data presented, how clinically meaningful do you find the efficacy outcomes (e.g., response rates, progression-free survival) for patients who have received multiple prior lines of therapy?
Added By: sara_adminBased on the data presented, how clinically meaningful do you find the efficacy outcomes (e.g., response rates, progression-free survival) for patients who have received multiple prior lines of therapy?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
